Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / March / Ophthalmology's Role in the Opioid Crisis
Health Economics and Policy Interview Research & Innovations

Ophthalmology’s Role in the Opioid Crisis

Retrospective cohort study investigates how ophthalmologists can provide potentially life-saving care to substance use disorder patients

By Alun Evans 3/19/2026 3 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Institutions
  • Top Thought Leaders

Clinical Scorecard: Ophthalmology’s Role in the Opioid Crisis

At a Glance

CategoryDetail
ConditionInjection drug use–associated endogenous endophthalmitis (IDU-EE)
Key MechanismsOpioid use, particularly fentanyl, linked to severe ocular disease and worse visual outcomes.
Target PopulationPatients with substance use disorders, particularly those who inject drugs.
Care SettingInpatient hospital settings, particularly emergency departments.

Key Highlights

  • IDU-EE presents a critical opportunity for early intervention in substance use disorders.
  • Fentanyl use is associated with worse visual outcomes compared to other drugs.
  • Aggressive ophthalmic treatment should be combined with addiction consultation.
  • Routine addiction consult involvement is recommended for managing IDU-EE.
  • Hospitalization is a key moment to connect patients with evidence-based addiction treatments.

Guideline-Based Recommendations

Diagnosis

  • Look for acute vision loss, floaters, eye pain, or photophobia in patients who inject drugs.
  • Utilize slit lamp and indirect ophthalmoscopy for diagnosis.

Management

  • Treat IDU-EE as a dual emergency with aggressive ophthalmic treatment and addiction consultation.

Monitoring & Follow-up

  • Ensure follow-up care and connection to harm-reduction services.

Risks

  • Failure to involve addiction consults may lead to missed treatment opportunities for opioid use disorder.

Patient & Prescribing Data

Patients hospitalized with IDU-EE and substance use disorders.

No opioid use disorder medication was administered without addiction consult involvement.

Clinical Best Practices

  • Normalize addiction consult involvement in the management of IDU-EE.
  • Utilize hospitalization as a touchpoint for initiating addiction treatments.

References

    This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

    Related Content

    Newsletters

    Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

    Newsletter Signup Image

    False

    Advertisement

    False

    Advertisement

    Explore More in Ophthalmology

    Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

    False

    Advertisement
    The Ophthalmologist
    Subscribe

    About

    • About Us
    • Work at Conexiant Europe
    • Terms and Conditions
    • Privacy Policy
    • Advertise With Us
    • Contact Us

    Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

    Affiliations:

    Specialties:

    Areas of Expertise:

    Contributions:

    Disclaimer

    The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: